Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).
暂无分享，去创建一个
David C. Smith | H. Scher | J. Bono | C. Higano | E. Small | C. Logothetis | D. Rathkopf | P. Corn | N. Vogelzang | D. George | E. Yu | M. Hussain | C. Sweeney | A. Harzstark | M. Gordon | Matthew R. Smith | N. Haas | C. Scheffold | A. Sartor | Yihua Lee